These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25617930)

  • 41. Triglyceride-Rich Lipoproteins.
    Kockx M; Kritharides L
    Cardiol Clin; 2018 May; 36(2):265-275. PubMed ID: 29609756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy and clinical trials.
    Ogunko A; Evans M
    Curr Opin Lipidol; 1998 Dec; 9(6):617-8. PubMed ID: 10075483
    [No Abstract]   [Full Text] [Related]  

  • 43. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
    Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum triglycerides and clinical benefit in lipid-lowering trials.
    Kesäniemi YA
    Am J Cardiol; 1998 Feb; 81(4A):70B-73B. PubMed ID: 9526818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
    Paillard F
    Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of icosapent ethyl on stroke risk: Different strokes for different folks?
    Lee M; Ovbiagele B
    J Neurol Sci; 2019 Jun; 401():127. PubMed ID: 31077950
    [No Abstract]   [Full Text] [Related]  

  • 49. Relevance of the reduction of triglycerides in the prevention of coronary heart disease.
    Kesäniemi YA
    Curr Opin Lipidol; 1998 Dec; 9(6):571-4. PubMed ID: 9868593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 51. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
    Colhoun H
    Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
    [No Abstract]   [Full Text] [Related]  

  • 52. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
    J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 55. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
    Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
    J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Triglycerides: risk factor or fellow traveler?
    Forrester JS
    Curr Opin Cardiol; 2001 Jul; 16(4):261-4. PubMed ID: 11574788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination lipid therapy in type 2 diabetes.
    Saely CH; Rein P; Drexel H
    N Engl J Med; 2010 Aug; 363(7):692; author reply 694-5. PubMed ID: 20701533
    [No Abstract]   [Full Text] [Related]  

  • 58. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 60. Evidence that triglycerides are an independent coronary heart disease risk factor.
    Cullen P
    Am J Cardiol; 2000 Nov; 86(9):943-9. PubMed ID: 11053704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.